This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D69.3 | Synonyms: Evans syndrome, combined autoimmune hemolytic anemia-thrombocytopenia syndrome, AIHA+ITP
Evans syndrome is named after the American hematologist Robert S. Evans and his colleagues, who in 1951 first described patients in whom autoimmune hemolytic anemia (AIHA) and thrombocytopenia occurred simultaneously or sequentially. In their 1951 paper, Evans et al. proposed that these two autoimmune blood cell destruction processes arise not from independent mechanisms but from a single immune abnormality.
With the introduction of the Coombs test in the 1950s~1970s, destruction of red blood cells and platelets by autoantibodies was confirmed as the pathogenesis of Evans syndrome. Subsequently, the respective mechanisms of autoimmune hemolytic anemia and immune thrombocytopenia were elucidated, and research was conducted on the mechanism by which the two diseases occur together in Evans syndrome.
In the 1990s~2000s, it began to be recognized that Evans syndrome may be associated with various underlying autoimmune or immunodeficiency diseases, such as systemic lupus erythematosus (SLE), common variable immunodeficiency (CVID), and autoimmune lymphoproliferative syndrome (ALPS). In particular, a high association with ALPS was confirmed in pediatric Evans syndrome.
In Korea, diagnosed cases of Evans syndrome began to be reported after the 2000s. The framework for recognizing the combined occurrence of autoimmune hemolytic anemia and immune thrombocytopenia as Evans syndrome in children and adults has been strengthened, and differential diagnosis from ALPS is emphasized especially in pediatric hematology.
The core pathogenesis of Evans syndrome is autoantibody production by autoreactive T cells and B cells. Anti-red blood cell autoantibodies (mainly IgG, warm-reactive) and antiplatelet autoantibodies bind to the surfaces of red blood cells and platelets, respectively, causing premature destruction in the spleen and liver. In some patients, antineutrophil antibodies are also present, and immune neutropenia appears as well.
| Underlying disease | Related immune abnormality | Features |
|---|---|---|
| Autoimmune lymphoproliferative syndrome (ALPS) | FAS, FASLG, CASP10 mutations | Most common cause in children, increased DNT cells |
| Systemic lupus erythematosus (SLE) | Anti-ds-DNA, antinuclear antibodies | Common in adult women |
| Common variable immunodeficiency (CVID) | Impaired antibody production + paradoxical autoimmunity | Accompanied by hypogammaglobulinemia |
| Antiphospholipid syndrome (APS) | Antiphospholipid antibodies | Accompanied by thrombosis risk |
| Chronic lymphocytic leukemia (CLL) | B cell abnormality | Adults, associated with malignancy |
| After hematopoietic stem cell transplantation | Associated with graft-versus-host disease | Occurs within months to years after transplantation |
Most Evans syndrome is a sporadic autoimmune disease that does not follow a specific inheritance pattern. However, when it appears as a manifestation of a specific genetic disease, it follows that mode of inheritance.
Evans syndrome is common in autoimmune lymphoproliferative syndrome (ALPS). Main ALPS causative genes: FAS (TNFRSF6, 10q24.1): ALPS-FAS, autosomal dominant/recessive. FASLG (TNFSF6, 1q24.3): ALPS-FASL. CASP10 (2q33.1): ALPS-CASP10. Because of impaired apoptosis in the FAS pathway, autoreactive lymphocytes are not eliminated and accumulate.
Evans syndrome can occur in CVID, and variants in genes such as TNFRSF13B (TACI), ICOS, and CD19 are identified in some cases. Evans syndrome can also appear in activated PI3Kδ syndrome (PIK3CD gain-of-function variants).
Some studies have reported an association between specific HLA types (HLA-DR3, HLA-DR5) and primary Evans syndrome, but no definitive conclusion has been reached.
Evans syndrome is a rare disease, and accurate prevalence data are limited. In children, Evans syndrome is estimated to develop in about 5~10% of patients with autoimmune hemolytic anemia. Progression to Evans syndrome is reported in about 1~2% of patients with immune thrombocytopenia.
It has two peaks, in childhood (mainly 5~10 years) and adulthood (mainly 40s~60s). In adults, it is slightly more common in women, presumably because of its association with female-predominant autoimmune diseases such as SLE. In children, there is no clear sex difference.
In Korea, Evans syndrome is classified as a rare disease, and domestic cases have been steadily reported in pediatric and adult hematology. Accompanying Evans syndrome has also been confirmed in domestic case reports of pediatric ALPS.
The core pathogenesis of Evans syndrome is the breakdown of immunological self-tolerance. Normally, T and B cells that react to self-antigens are eliminated or suppressed by central or peripheral tolerance mechanisms. Defects in these mechanisms allow autoreactive lymphocytes to proliferate and produce autoantibodies.
When warm-reactive autoantibodies (mainly IgG) bind to antigens on the red blood cell surface (Rh antigens, band 3 protein, etc.), splenic monocyte-macrophages recognize the red blood cells through IgG Fc receptors and phagocytose them (extravascular hemolysis). When complement activation is severe, intravascular hemolysis also occurs.
Antiplatelet IgG autoantibodies bind to platelet membrane glycoproteins such as GPIIb/IIIa and GPIb/IX, causing premature destruction in the spleen. Antibodies may also bind to megakaryocytes and suppress platelet production itself.
Reduced numbers and function of CD4+CD25+FOXP3+ regulatory T cells (Tregs) have been reported in patients with Evans syndrome. Reduced Treg function leads to failure to suppress autoreactive effector T cells and B cells.
Rapidly progressing anemia: pallor, fatigue, dyspnea, palpitations. Jaundice due to hemolysis (including scleral icterus). Dark urine (hemoglobinuria, with intravascular hemolysis). Splenomegaly and hepatomegaly.
Bleeding tendency: petechiae, purpura, bruising. Epistaxis, oral mucosal bleeding. Menorrhagia (women). With severe thrombocytopenia, risk of visceral bleeding and intracranial hemorrhage.
When AIHA and ITP occur simultaneously, pallor, jaundice, and bleeding appear together. The combination of severe anemia and thrombocytopenia has a more serious clinical course than either disease alone. In some patients, autoimmune neutropenia is also present, increasing the risk of infection.
With SLE: butterfly rash, photosensitivity, arthralgia, nephritis. With ALPS: chronic lymphadenopathy, splenomegaly, nonmalignant lymphoproliferation. With CVID: recurrent infections, symptoms related to hypogammaglobulinemia.
The main signs are pallor (anemia), jaundice (scleral icterus), splenomegaly (site of red blood cell and platelet destruction), and lymphadenopathy (with underlying ALPS or accompanying lymphoma). Cutaneous petechiae, purpura, and bruising suggest thrombocytopenia.
| Test item | Result |
|---|---|
| Hemoglobin (Hb) | Decreased (hemolytic anemia) |
| Platelet count | Decreased (<100,000/μL, <20,000/μL when severe) |
| Reticulocyte count | Increased (hemolytic response) |
| Direct Coombs test (DAT) | Positive (IgG alone, or IgG+C3) |
| Indirect bilirubin | Increased |
| LDH | Increased (hemolysis marker) |
| Haptoglobin | Decreased |
| Peripheral blood smear | Spherocytes, decreased platelet count |
Bone marrow examination shows erythroid hyperplasia (compensation for hemolysis), increased megakaryocytes (response to platelet consumption), and rarely findings of lymphocyte proliferation.
Evans syndrome is suspected when thrombocytopenia develops at the same time in a patient with confirmed hemolytic anemia, or when hemolytic anemia newly develops in a patient with immune thrombocytopenia.
A complete blood count (CBC), reticulocyte count, and peripheral blood smear are performed. The direct Coombs test (DAT) is the key screening test for AIHA. Biochemical evidence of hemolysis is confirmed with indirect bilirubin, LDH, and haptoglobin.
An autoimmune panel (ANA, anti-dsDNA, antiphospholipid antibodies, complement C3/C4), serum immunoglobulins (IgG, IgA, IgM), lymphocyte phenotyping (when ALPS is suspected, double-negative T cell proportion and Fas/FasL function testing), and EBV and CMV viral testing are performed.
Evans syndrome is diagnosed when both of the following two conditions are met.
However, the two diseases may occur simultaneously or sequentially.
Direct Coombs test: IgG or IgG+C3 positivity is characteristic of AIHA. Platelet antibody testing (PAIgG, GPIIb/IIIa antibodies): aids ITP diagnosis. Indirect Coombs test (IAT) to search for anti-red blood cell antibodies in serum.
When ALPS is suspected: confirm double-negative T (DNT) cells (CD3+TCRαβ+CD4-CD8-, >1.5%) by flow cytometry, elevated serum vitamin B12, FAS/FASLG gene sequencing. When SLE is suspected: ANA, anti-dsDNA, complement, renal function, urinalysis. When CVID is suspected: quantitative serum immunoglobulins, B cell phenotyping.
Bone marrow examination may be performed to exclude hematologic malignancy. Lymphoma, leukemia, and multiple myeloma are excluded in the bone marrow.
Corticosteroids (prednisone or dexamethasone) are the first-line treatment. Prednisolone is started at 1~2mg/kg/day and tapered after response. For acute severe episodes, high-dose intravenous methylprednisolone pulse therapy is given.
When refractory to steroids and immunosuppressants, splenectomy may be effective for both AIHA and ITP. However, in Evans syndrome there is a risk of relapse after splenectomy, so the indication must be chosen carefully.
In ALPS-associated Evans syndrome, sirolimus (mTOR inhibitor) has been proven effective in reducing DNT cells and improving autoimmune cytopenias.
Allogeneic or autologous HSCT is considered in patients with underlying immune defects such as ALPS or CVID or with severe relapsing Evans syndrome. Successful cases of HSCT have been reported in severe pediatric Evans syndrome, but transplant-related risks must be considered.
Evans syndrome often follows a relapsing course, and its prognosis tends to be worse than that of AIHA or ITP alone. In children, about 50~70% of patients experience relapse, and some follow a chronic course.
With the introduction of modern treatments such as rituximab, short-term response rates have improved, but maintaining long-term remission remains challenging. Repeated treatment is needed at relapse, and steroid dependence affects quality of life.
With ALPS, long-term management is possible with sirolimus treatment. With SLE, the activity of the SLE itself determines prognosis. With malignancy, the prognosis of the underlying malignancy predominates.
Deaths related to Evans syndrome are mainly due to severe bleeding (intracranial hemorrhage), sepsis (a complication of immunosuppressive treatment), and progression of underlying malignancy.
Relapse is prevented with maintenance immunosuppressive treatment (mycophenolate mofetil, azathioprine, low-dose steroids). Some studies report that maintenance rituximab (at 6~12-month intervals) is effective in preventing relapse.
During immunosuppressive treatment, prophylactic antibiotics (trimethoprim-sulfamethoxazole) against Pneumocystis pneumonia (PJP) are given. Vaccinations against influenza, pneumococcus, varicella, etc. After splenectomy, vaccination against pneumococcus, Haemophilus, and meningococcus and prophylactic antibiotics are given.
Treatment of the underlying disease, such as suppressing SLE activity and immunoglobulin replacement therapy for CVID, contributes to preventing relapse of Evans syndrome.